| name | endo-pa-mra-first-line-spironolactone |
| description | Recommends spironolactone as first-line mineralocorticoid receptor antagonist for initial medical therapy of primary aldosteronism due to low cost and widespread availability. Use when a clinician queries which MRA to start for a patient with PA requiring medical therapy. |
Choose spironolactone as first-line MRA for PA medical therapy
STEP 1 — Gather Information
Confirm PA diagnosis (elevated ARR with suppressed renin and inappropriately high aldosterone), assess need for medical therapy (patient not surgical candidate, declines surgery, or has bilateral PA), screen for spironolactone contraindications (serum K+ >5.0 mmol/L, eGFR <30 mL/min/1.73m², pregnancy), and evaluate patient-specific concerns about androgen/progesterone-mediated side effects (e.g., male patient, gynecomastia history).
STEP 2 — Rule In / Rule Out
If any contraindication to spironolactone exists (hyperkalemia, severe renal impairment, pregnancy) → Rule out spironolactone; consider alternative MRA (eplerenone) or other agents. If no contraindications but patient expresses significant concern about spironolactone side effects → Consider a more selective MRA (eplerenone) despite higher cost. Otherwise → Proceed with spironolactone as first-line.
STEP 3 — Classify or Stratify
Classify patient as: (A) No contraindications and no major side‑effect concerns → Spironolactone preferred; (B) Contraindication present → Alternative therapy needed; (C) No contraindication but side‑effect aversion → Selective MRA (eplerenone) may be chosen despite cost.
STEP 4 — Decide
For group (A): Initiate spironolactone 12.5–25 mg daily, titrate every 8–12 weeks based on BP and renin (target renin rise >1.0 ng/mL/h or >10 mU/L), monitor K+, creatinine, and BP every 2–3 months. For group (B): Choose eplerenone 25–50 mg twice daily or another appropriate agent, following similar titration and monitoring. For group (C): Shared decision‑making; if selective MRA chosen, initiate eplerenone 25–50 mg twice daily and titrate to equivalent MR blockade.
Clinical Guardrails / Mimics / Pitfalls
Do not initiate spironolactone in pregnancy, hyperkalemia (K+ >5.0 mmol/L), or severe renal impairment (eGFR <30) without specialist advice; do not ignore rising serum creatinine or worsening hyperkalemia during titration; do not fail to monitor renin as a marker of MR blockade; do not assume all MRAs are interchangeable in side‑effect profile—spironolactone carries higher risk of gynecomastia and menstrual irregularities.
Concrete Clinical Example
A 52‑year‑old woman with bilateral PA confirmed by AVS, hypertension on three drugs, desires medical therapy, K+ 4.2 mmol/L, eGFR 78 mL/min/1.73m², no pregnancy, no prior gynecomastia concerns. Starts spironolactone 25 mg daily; after 8 weeks BP improves from 158/96 to 138/84 mmHg, K+ 4.6 mmol/L, renin rises from 0.2 to 1.4 ng/mL/h. Dose increased to 50 mg daily; after another 8 weeks BP 130/80 mmHg, K+ 4.8 mmol/L, renin 2.1 ng/mL/h. Continues on spironolactone monotherapy.
Source: Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, DOI: 10.1210/clinem/dgaf284
